Barberani F, Della Spoletina A, Rossi P, Valentini P, Fatale G P
Int J Tissue React. 1983;5(3):309-13.
Pirenzepine, a new antimuscarinic drug which selectively binds to gastric mucosal muscarinic receptors, has been found to be as effective as cimetidine in promoting the healing of duodenal ulcer. Since recurrence is the major clinical problem in duodenal ulcer, the authors have performed a double-blind randomized study to evaluate the relapse rates during a follow-up period of six months after healing with pirenzepine. Fifty patients were admitted to the trial and randomly allocated to placebo (group C) or pirenzepine (50 mg daily, group A, and 100 mg daily, group B). Forty-four patients completed the trial. During the six months treatment 9 patients had relapses. No significant difference was found between three groups. No side-effects were observed. The 6-month treatment with 50 mg or 100 mg of pirenzepine was well tolerated and without side-effects. The relapse rate during the six months after healing was very low and no significant difference was found between relapse rates in the three treatment groups. These results suggest that seasonal treatment with pirenzepine will prevent duodenal ulcer relapses, increase patient compliance and reduce the social cost of peptic ulcer disease. Additional studies over 12 months of treatment should be undertaken to verify our findings.
哌仑西平是一种新型抗胆碱能药物，能选择性地与胃黏膜的毒蕈碱受体结合，现已发现其在促进十二指肠溃疡愈合方面与西咪替丁疗效相当。由于复发是十二指肠溃疡的主要临床问题，作者进行了一项双盲随机研究，以评估哌仑西平治愈后6个月随访期内的复发率。50名患者参加了试验，随机分为安慰剂组（C组）或哌仑西平组（A组每日50毫克，B组每日100毫克）。44名患者完成了试验。在6个月的治疗期间，9名患者复发。三组之间未发现显著差异。未观察到副作用。50毫克或100毫克哌仑西平治疗6个月耐受性良好，无副作用。治愈后6个月内的复发率非常低，三个治疗组的复发率之间未发现显著差异。这些结果表明，哌仑西平的阶段性治疗将预防十二指肠溃疡复发，提高患者依从性并降低消化性溃疡疾病的社会成本。应进行超过12个月治疗的进一步研究以验证我们的发现。
